CDC and FDA pause Johnson and Johnson vaccine over rare blood clot cases

The CDC and FDA recommend pausing administration of the Johnson & Johnson COVID-19 vaccine after six women develop a rare but serious blood-clotting disorder after receiving the one-dose shot out of 6.8 million doses administered. The pause lasts 11 days before the agencies conclude the vaccine's benefits outweigh the risks for most adults. The episode fuels vaccine hesitancy at a critical moment, with the Biden administration pushing hard to reach 70% adult vaccination by July 4. The advisory committee ultimately adds a warning about the rare risk and recommends the vaccine to resume, with preference given to Pfizer and Moderna.